Tesamorelin

Stabilized GHRH analog peptide

Tesamorelin is classified as a stabilized growth-hormone-releasing hormone (GHRH) analog peptide. It is a modified GHRH(1-44) analog described in the literature as having improved stability relative to native GHRH, and it appears in preclinical studies of the somatotropic axis. This page is background about the molecule as a research material and is not medical guidance and not intended for human or animal use.

Classification and structure

Tesamorelin is a synthetic analog of human GHRH(1-44) bearing an N-terminal modification that increases its resistance to enzymatic degradation. It is classified as a GHRH-receptor-directed analog and is structurally longer than the GHRH(1-29)-based analogs, retaining the full-length active sequence with a stabilizing group.

Areas of research

In the scientific literature this peptide appears across the following research areas.

• GHRH-receptor research — Investigated in laboratory models of GHRH-receptor interaction within the somatotropic axis.
• Peptide stabilization — Appears in studies of N-terminal modifications that increase resistance to enzymatic degradation.
• Analytical characterization — Used as a reference material in peptide purity, identity, and stability studies.

As always in this library, describing a compound as “studied in” an area is a statement about where scientific attention has gone — not a claim that it produces any result in humans or animals.

Handling and verification

Store lyophilized peptide cold and protected from light per standard peptide handling practice. Every in-stock lot ships with a verifiable third-party certificate of analysis (COA).